# Phase 1 hematologic cancer trials recruiting: 57 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials in phase 1 for hematologic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 hematologic cancer trials: 57 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/hematologic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 57
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941531 | T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies. | St. Jude Children's Research Hospital | Phase 1 | Not yet recruiting | Lymphoma, AML, T-ALL, Hematologic Malignancy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941531) |
| November 17, 2026 | NCT07940738 | Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | Recruiting | Hematologic Malignancy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940738) |
| November 6, 2026 | NCT07923071 | A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment | Syndax Pharmaceuticals | Phase 1 | Not yet recruiting | Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923071) |
| September 9, 2026 | NCT07809906 | Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression | Orum Therapeutics USA, Inc. | Phase 1 | Recruiting | CD123+ Acute Myeloid Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809906) |
| September 9, 2026 | NCT07809139 | A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies | Nanjing Miracle Biotechnology Co., Ltd. | Phase 1 | Not yet recruiting | Hematological Malignancies | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809139) |
| September 9, 2026 | NCT07809126 | A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in... | Nanjing Miracle Biotechnology Co., Ltd. | Phase 1 | Not yet recruiting | Hematological Malignancies | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809126) |
| August 7, 2026 | NCT07753148 | Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic... | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753148) |
| June 29, 2026 | NCT07672964 | CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation | Ruijin Hospital | Phase 1 | Not yet recruiting | Hematologic Malignancy, Haplo-identical HCT | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672964) |
| May 7, 2026 | NCT07572006 | A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies | Janssen Research & Development, LLC | Phase 1 | Recruiting | Hematologic Neoplasms | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572006) |
| April 16, 2026 | NCT07532746 | A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies | Kousai Bio Co., Ltd. | Phase 1 | Not yet recruiting | Relapsed or Refractory EBV-associated Hematological Malignancies | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532746) |
| March 20, 2026 | NCT07485504 | Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies | Tcelltech Inc. | Phase 1 | Not yet recruiting | Relapsed or Refractory Hematologic Malignancies | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485504) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| January 5, 2026 | NCT07316907 | A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Hematologic Malignancies, Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07316907) |
| December 19, 2025 | NCT07294300 | A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Relapsed/Refractory Hematological Malignancies | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294300) |
| December 2, 2025 | NCT07257419 | CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for... | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257419) |
| December 1, 2025 | NCT07255898 | A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma, Hematologic Malignancies | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255898) |
| November 28, 2025 | NCT07254793 | Prophylactic DLI-X for Leukemia Relapse After HCT | University of Arizona | Phase 1 | Recruiting | Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254793) |
| September 29, 2025 | NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Incyte Corporation | Phase 1 | Recruiting | Solid Tumors, Hematologic Malignancies | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195916) |
| September 15, 2025 | NCT07173595 | A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Relapsed or Refractory Hematologic Malignancies | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173595) |
| September 9, 2025 | NCT07162038 | Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Hematologic Malignancies, Hematologic Neoplasms | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07162038) |
| July 4, 2025 | NCT07052370 | TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted... | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Hematologic Malignancy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052370) |
| July 1, 2025 | NCT07044544 | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | University of Alabama at Birmingham | Phase 1 | Recruiting | Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044544) |
| June 25, 2025 | NCT07036133 | Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and... | Acrotech Biopharma Inc. | Phase 1 | Recruiting | Advanced Solid Tumors, Hematologic Malignancies | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07036133) |
| June 11, 2025 | NCT07014449 | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | Hangzhou Weben Pharma Co., Ltd | Phase 1 | Recruiting | AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07014449) |
| April 1, 2025 | NCT06904066 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms... | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06904066) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| St. Jude Children's Research Hospital | 4 |
| National Cancer Institute (NCI) | 3 |
| Nanjing Miracle Biotechnology Co., Ltd. | 2 |
| Kura Oncology, Inc. | 2 |
| University of Alabama at Birmingham | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 2 |
| Hangzhou Weben Pharma Co., Ltd | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| Institut de Recherches Internationales Servier | 1 |
| Immunome, Inc. | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| The Third Affiliated Hospital of Southern Medical University | 1 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Therapeutic Advances in Childhood Leukemia Consortium | 1 |
| Zhejiang Provincial People's Hospital | 1 |
| Kousai Bio Co., Ltd. | 1 |
| [Sinocelltech Ltd.](https://specstream.ai/data/clinical-trials/company/sinocelltech-ltd) | 1 |
| Shenzhen TargetRx Co., Ltd. | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| Orum Therapeutics USA, Inc. | 1 |
| University Hospital, Geneva | 1 |
| Ruijin Hospital | 1 |
| Vincerx Pharma, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 30 |
| China | 21 |
| France | 4 |
| Australia | 3 |
| Belgium | 3 |
| Denmark | 3 |
| Spain | 3 |
| United Kingdom | 3 |
| Italy | 2 |
| Switzerland | 1 |
| Canada | 1 |
| Poland | 1 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tenant and eviction law firms in the United States](https://specstream.ai/data/businesses/tenant-and-eviction-law-firms/united-states)
- [Cheesesteak restaurants in the United States](https://specstream.ai/data/businesses/cheesesteak-restaurants/united-states)
- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
- [B2B science and technology companies in the United States](https://specstream.ai/data/businesses/b2b-science-and-technology-companies/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
